CN105326888A - Medicinal composition for treating child phlegm-heat obstructing lung type asthma - Google Patents
Medicinal composition for treating child phlegm-heat obstructing lung type asthma Download PDFInfo
- Publication number
- CN105326888A CN105326888A CN201510871918.8A CN201510871918A CN105326888A CN 105326888 A CN105326888 A CN 105326888A CN 201510871918 A CN201510871918 A CN 201510871918A CN 105326888 A CN105326888 A CN 105326888A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- phlegm
- children
- lung type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention discloses a medicinal composition for treating child phlegm-heat obstructing lung type asthma and a preparation method thereof. The medicinal composition is prepared from climacium dendroides, bidens frondosa, stevioside, taraxerol and fructus cassiae fistulae. The medicinal composition can be prepared into various dosage forms according to a conventional preparation process, and is remarkable in treatment effect on child phlegm-heat obstructing lung type asthma.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to and a kind ofly treat pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma and preparation method thereof.
Background technology
Asthma is TCM Pediatrics commonly encountered diseases, every disease that is clinical manifestation with cough with asthma tachypnea, wheezing sound in the throat, even failing to lie flat due to dyspnea, opening mouth and lifting shoulder due to dyspnea, cyanotic lips can be included into traditional Chinese medical science asthma and carry out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, comprises doctor trained in Western medicine asthmatic bronchitis, bronchiolitis, bronchial asthma etc.Children with asthma in recent years sickness rate, case fatality rate increases year by year, has become one of disease that vast department of pediatrics medical worker pays close attention to.Doctor trained in Western medicine uses hormone Inhalation in Treating to asthma in acute attack stage, dyspnea with rapid and short breath symptom controls ideal, but cough, abundant expectoration, pulmonary's rale sound are difficult to dissipation etc. and there is no good Therapeutic Method, and the glucocorticoid of prolonged application recommended dose also can produce systemic adverse reactions in various degree, symptoms of asthma still can not be made to control completely even if indivedual infant sucks the glucocorticoid exceeding recommended dose.The exploration effective Therapeutic Method of Chinese medicine and square medicine are the directions of middle medical circles effort at present.
Children's's the lung being usually insufficient, weakened defensive QI, hedge loosens, and cold warming up does not know self-regulated, is very easily subject to exopathogen invasion and attack, makes impaired depurative descending of lung QI, disturbance of lung-QI, abnormal rising of lung-QI, priming latent phlegm, and mental disorder is handed over and hindered in air flue, and ascending or descending movement of vital Qi is unfavorable, so that coughing and wheezing, wheezing sound in the throat, sends out as asthma.Children's spoils in Modern Family, usually feeds the food pursuing high protein, high nutrition, and children's all can hinder spleen to transport addicted to food salty sour savoury, fish raw meat stimulating food etc., makes raw expectorant heat, brings out phlegm-heat obstructing lung type asthma.Say as " Confucian's Duties to Their Parents ": " rich and honour person, the saliva of meaning is coughed, and polydipsia eats dense taste, and heat-phlegm becomes also." in addition primary disease be mainly in preschooler, the reflection of this age period children cough is poor, and expectoration is limited in one's ability, the sputum in air flue can not be excreted, and is also abundant expectoration when causing asthma attack, the treatment difficult point that disappears of wheezing sound in the throat phenomenon difficulty.
10000 years moss: this product is ten thousand Nian Xian sections, 10000 years Rhodobryum plants, 10000 years moss Climaciumdendroides(Hedw.) plant of Web.etMohr ［ LeskeadendroidesHedw. ］.Spring, summer gather, and clean, dry.[nature and flavor] are bitter; Cold.[function cures mainly] removing damp-heat; Relaxing muscles and tendons and activating QI and blood in the collateral.Main air wets impairment caused by overstrain; Bones and muscles pain.[chemical analysis] is containing cupreol (β-sitosterol), stigmasterol (stigmasterol), ergosterol (ergosterol), campesterol (campesterol), cyclolaudenol (cyclolaudenol), the nor-cyclolaudenol of 31-(31-norcyclolaudenol), and metallic elements of ferrum, manganese, zinc, copper etc.[former phytomorph] plant is thick in tree-like, and subterraneous stem crawls to grow wild, tool rhizoid and film quality squamous lobule.The aerial stem of plant is upright, multi-branched, and up to 15-20cm, branch gathers green palea.The leaf on stem top and the blade of branched base part are wide ovum shape triangle or ovum shape lanceolar, and base portion is slightly downward.Middle rib is single, reaches and stops before blade tip, the narrow rhombus of blade top cell, and leaf bight cell is circular, semi-transparent clear.The blade on branch top is less, and long and narrow lanceolar, leaf edge sawtooth reaches in middle part.Dioecism.Seta is elongated, long 2-4cm, red; Sporangium is upright, and long column shape, has more; The female shape of opercule height circle; Capsule balaclava shape, the full sporangium of clad.Record in Chinese medicine voluminous dictionary.
Large Herba Bidentis Tripartitae: this product is the dry aerial parts of the large Herba Bidentis Tripartitae BidensfrondosaL. of feverfew.6 ~ JIUYUE is gathered, and Herb or cutting, dry.[nature and flavor] are bitter, flat.[function with cure mainly] QI invigorating, heat clearing away.For body nihility power, night sweat, spitting of blood, dysentery.[character] this product Herb is logical straight, top tool branch.Stem is cylindrical, bottom tool wane and in class square, diameter 0.2 ~ 1.5cm, surperficial light brown to mulberry, tool longitudinal grin; Matter is crisp, frangibility, section canescence, the wide or hollow of marrow.Leaf is to life, and a winglike compound leaf, lobule 3 ~ 5 splits, and multireel is bent or broken. and in lanceolar after complete blade flattens, tip is gradually sharp, and there is rough sawn tooth at edge, and the back side is by sparse pubescence; The obvious petiolule of tool.Head inflorescence top is raw or axil is raw, and phyllary is most, outer lobate.Achene is flat, the shape of falling ovum wedge shape. and long 6 ~ llmm, top prickle 2 pieces, long 2 ~ 4mm, there is glochid both sides.Feeble QI, mildly bitter flavor.Record in Shanghai City Chinese crude drug standard 1994 (Shanghai Health Bureau).
Sausage fruit: this product is the dry mature fruit of leguminous plant Cassia fistula L. CassiafistulaL..Winter gathers when fruit is ripe, dries.[nature and flavor] are sweet, micro-pungent, cool.[function with cure mainly] removing heat from the liver, removing toxic substances, detumescence, captures.For hepatitis, liver poisoning, constipation, limb edema.[character] this product is cylindrical.Complete person long 30 ~ 50cm, diameter 1.5 ~ 2.5cm, top point, base portion has short fruit stem.Surface crineous, to pitchy, is smoothly with gloss, and the very obvious annular shallow slot of tool, it is obvious that abdomen carries on the back two sutures.Matter is hard, broken, section tool yellowish-brown tabula.1, each tool seed of every two compartment.Sarcocarp red and white around seed or yellow green are to yellowish-brown.Seed is attached on ventral suture by short-term shape funicle, often comes off.Seed is oval and slightly flat, and yellowish-brown is to reddish dark brown, smooth, and the wrinkle of both sides tool slightly protuberance, has shallow groove up and down.Matter is hard, and heat water produces the colloid membrane of transparent easy stripping, the flourishing cutin sample of endosperm.Sarcocarp gas is special, sweet in the mouth, hardship, puckery, sour.Record in health Tibetan medicine standard promulgated by the ministries or commissions of the Central Government (first), standard number: WS3-BC-0109-95.
Taraxerol (Taraxerol): CAS 127-22-0, molecular formula C
30h
50o, molecular weight 426.73.[pharmacological action] antiulcer, anti-gastric acid secretion.[ingredient origin] feverfew Europe Radix Taraxaci; Ebenaceae Diospyros plant, Fagaceae platymiscium, Canarium plant.
Stevioside (Stevioside): CAS 57817-89-7, molecular formula C
38h
60o
18, molecular weight 804.87.[pharmacological action] blood sugar lowering; Resisting hypertension; Enhance metabolism; Be used for the treatment of hyperchlorhydria.[ingredient origin] Folium Stevlae Rebaudianae Eupatoriumrebaudianum, Folium hydrangeae strigosae Rubussuavissimus.
2 crude drug chemical constitutions:
Taraxerol (Taraxerol) stevioside (Stevioside).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment children's phlegm-heat obstructing lung type asthma and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment children's phlegm-heat obstructing lung type asthma are:
10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions.
Preferably be used for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, be made up of the crude drug of following weight portion:
10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions.
Treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that the treatment children's phlegm-heat obstructing lung type asthmatic medicament that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Preferably treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat children's's phlegm-heat obstructing lung type asthmatic medicament.
Medicine composite for curing children's phlegm-heat obstructing lung type asthma is evident in efficacy: medicine composite for curing phlegm-heat obstructing lung type asthma, not only on comprehensive therapeutic effect, be obviously better than matched group, and at elimination sputum, alleviate breath with cough, wheezing sound in the throat single disease improvement aspect curative effect is also better than matched group.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 515g large Herba Bidentis Tripartitae 485g stevioside 26g taraxerol 18.5g sausage fruit 160g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 500g large Herba Bidentis Tripartitae 490g stevioside 22g taraxerol 19g sausage fruit 140g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are: 10000 years moss 530g large Herba Bidentis Tripartitae 480g stevioside 28g taraxerol 18g sausage fruit 180g;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 163g, adds starch 47g, mixing, granulates, dry, adds microcrystalline Cellulose 20g, magnesium stearate 2g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 145g, adds starch 65g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 185g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 25g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 4 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.2cm apart from liquid level, drips speed with per minute 58 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Large Herba Bidentis Tripartitae 410 weight portion taraxerol 16 weight portion sausage fruit 90 weight portions.
Embodiment 8: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Stevioside 2 weight portion taraxerol 4 weight portion sausage fruit 160 weight portions.
Embodiment 9: the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of children's phlegm-heat obstructing lung type asthma are:
Stevioside 5 weight portion taraxerol 3 weight portion sausage fruit 100 weight portions.
Experimental example 1: the experimental study for the treatment of children's phlegm-heat obstructing lung type asthma
1 clinical data
1.1 physical data
70 routine infants all from this provincial hospital Pediatric Clinic in year April in April, 2011 to 2012, all meet doctor trained in Western medicine Diagnosing Asthma standard and traditional Chinese medical science phlegm-heat obstructing lung type Diagnosing Asthma standard.Treatment group and each 35 examples of matched group are divided at random by 1: 1.Man 18 example in matched group, female 17 example; Year mean age (3.85 ± 2.45); Average course of disease (4.12 ± 1.69) d.Man 17 example in treatment group, female 18 example; Year mean age (4.21 ± 2.79); Average course of disease (3.95 ± 1.81) d.2 groups of infants are through statistical analysis in sex, age, the course of disease etc., and difference no statistical significance (P > 0.05), has comparability.
1.2 diagnostic criteria
1.2.1 Western medicine diagnose standard
With reference to the diagnostic criteria of " pediatrics " infantile asthma.1. the panting of recurrent exerbation, tachypnea, uncomfortable in chest or cough, many with contact allergen, cold air, physics or chemical irritation, viral upper and lower respiratory tract infection, to move etc. relevant.2. two lung audible and being dispersed in or the wheezing sound of diffusivity based on expiratory phase, expiratory phase prolongation during outbreak.3. bronchodilators has significant curative effect.Panting 4. caused by other diseases, tachypnea, uncomfortable in chest or cough.5. for the infant of atypical symptom, hear and wheezing sound person in pulmonary simultaneously, following any 1 Bronchodilation Test can be adopted as one sees fit to assist diagnosis, if positive diagnosable be asthma: quick-acting beta 2 receptor agonist atomized soln or aerosol suction, with 0.1% epinephrine 0.01mL/kg subcutaneous injection (maximum be no more than 0.3mL/ time).In 15 ~ 30min after carrying out above any a kind of test, obviously alleviate if panted, wheezing sound obviously minimizing person is positive.
1.2.2 traditional Chinese medical science Diagnosing Asthma standard
Formulate with reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect ".1. often have the premonitory symptom such as sneeze, cough before outbreak, or break out night.Wheezing between larynx during outbreak, dyspnea, expectoration is not well, very then can not put down sleeping, dysphoria etc.2. normal because of climate flip, suffer from cold or contact the factors such as some allergin and bring out.3. infancy stage eczema history or family's allergies can be had.4. heart and lung auscultation: two fullness of the lung cloth wheezing sounds, prolonged expiration, or hear and moist rales, increased heart rate.5. bronchial asthma, total white blood cells is normal, and eosinophilic granulocyte can increase, and suspicious allergen skin test is often positive.During companion's pulmonary infection, blood leukocytes sum and neutrophilic granulocyte can increase.
1.2.3 TCM syndrome diagnostic criteria
With reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect " syndrome of phlegm-heat obstructing lung: cough with asthma wheezing, yellowish thick sputum, xerostomia pharynx is red, or it is flushing to generate heat, and red tongue, yellow and thin fur or yellow greasy, slippery and rapid pulse, fingerprint is purple.
2 methods
2.1 matched group
Instruct according to asthma in acute attack stage treatment in pediatrics branch of Chinese Medical Association pneumatology group " During Prevention of Asthma in Children routine (trying) ", beclometasone μ g every day 200 ~ 400, albuterol sheet 0.1 ~ 0.15mg/kg, every day 2 ~ 3 times.
2.2 treatment group
Give pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20110130) 1-2 agent every day, every agent 3g, every agent 100mL that adds water dissolves, and points 3 times oral, and 7d is l the course for the treatment of, serve on 1 course for the treatment of.
2 groups of period in a medicine all avoid pungent food, raw meat is cold, greasy product.
2.3 statistical method
Use SPSS16.0 software to carry out statistical analysis, ranked data adopt Ridit inspection, and enumeration data adopts χ
2inspection, with P < 0.05 for difference has statistical significance.
3 results
3.1 criterion of therapeutical effect
With reference to the standard formulation in State Administration of Traditional Chinese Medicine's " new Chinese medicine guideline of clinical investigations ".Recovery from illness: transference cure, auscultation of lung is without wheezing sound.Effective: symptom is clearly better, pulmonary's wheezing sound obviously reduces.Effective: symptom takes a turn for the better to some extent, pulmonary's wheezing sound reduces.Invalid: symptom and wheezing sound are all without improvement.
3.2 disease criterions of therapeutical effect
Clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear, disease integration reduces >=95%.Effective: tcm clinical practice symptom, sign are obviously improved, disease integration reduces >=70%.Effective: tcm clinical practice symptom, sign all take a favorable turn, disease integration reduces >=30%.Invalid: to increase the weight of even tcm clinical practice symptom, sign are all not improved, disease integration reduces < 30%.
After 3.32 groups of infant treatments, comprehensive therapeutic effect compares
Treatment group recovery from illness 13 example, effective 13 examples, effective 4 examples, invalid 5 examples, total effective rate is 85.7%; Matched group recovery from illness 6 example, effective 8 examples, effective 12 examples, no effect 9, total effective rate is 74.3%.After 2 groups of treatments, comprehensive therapeutic effect comparing difference has statistical significance (P < 0.05).Refer to table 1.
After table 1 liang group infant treatment, comprehensive therapeutic effect compares (example)
| Group | n | Recovery from illness | Effective | Effectively | Invalid | Total effective rate/% |
| Matched group | 35 | 6 | 8 | 12 | 9 | 74.3 |
| Treatment group | 35 | 13 | 13 | 4 | 5 | 85.7 * |
Note: compare with matched group
*p < 0.05.
TCM syndrome comparitive study after 3.42 groups of infant treatments
Treatment group clinical recovery 18 example, effective 8 examples, effective 5 examples, invalid 4 examples, total effective rate is 88.6%; Matched group recovery from illness 8 example, effective 3 examples, effective 15 examples, no effect 9, total effective rate is 74.3%.After 2 groups of treatments, TCM syndrome comparitive study difference has statistical significance (P < 0.05).Refer to table 2.
TCM syndrome comparitive study (example) after table 2 liang group infant treatment
| Group | n | Recovery from illness | Effective | Effectively | Invalid | Total effective rate/% |
| Matched group | 35 | 8 | 3 | 15 | 9 | 74.3 |
| Treatment group | 35 | 18 | 8 | 5 | 4 | 88.6 * |
Note: compare with matched group
*p < 0.05.
Result shows, medicine composite for curing phlegm-heat obstructing lung type asthma, is not only obviously better than matched group on comprehensive therapeutic effect, and at elimination sputum, alleviate breath with cough, wheezing sound in the throat single disease improvement aspect curative effect is also better than matched group, can in clinical middle Coryza Treated by Syndrome Differentiation phlegm-heat obstructing lung type asthma.
Claims (8)
1. treat a pharmaceutical composition for children's's phlegm-heat obstructing lung type asthma, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions.
2. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions.
3. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of children's's phlegm-heat obstructing lung type asthma according to claim 1, is characterized in that the treatment children's phlegm-heat obstructing lung type asthmatic medicament that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 500-530 weight portion large Herba Bidentis Tripartitae 480-490 weight portion stevioside 22-28 weight portion taraxerol 18-19 weight portion sausage fruit 140-180 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
6. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: 10000 years moss 515 weight portion large Herba Bidentis Tripartitae 485 weight portion stevioside 26 weight portion taraxerol 18.5 weight portion sausage fruit 160 weight portions;
Preparation method: get 10000 years moss by crude drug proportioning, large Herba Bidentis Tripartitae, stevioside, taraxerol, sausage fruit, mixing, with weight percent concentration 58% ethanol as solvent, extract at 47 DEG C of warm macerating, extraction time is 8 times, each extraction time is 2 hours, each solvent load is 45 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.16, filter, medicinal liquid is by CLX-11 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting CLX-11 macroporous adsorptive resins of weight percent concentration 77% again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
7. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of children's's phlegm-heat obstructing lung type asthma according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats children's's phlegm-heat obstructing lung type asthmatic medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510871918.8A CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510871918.8A CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105326888A true CN105326888A (en) | 2016-02-17 |
Family
ID=55277794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510871918.8A Withdrawn CN105326888A (en) | 2015-12-03 | 2015-12-03 | Medicinal composition for treating child phlegm-heat obstructing lung type asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105326888A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581100A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for laryngitis treatment and preparation method thereof |
| CN106692261A (en) * | 2016-12-10 | 2017-05-24 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for treating laryngitis and preparation method thereof |
| CN106727774A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of pharyngitis and preparation method thereof |
| CN106727859A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof |
| CN106852946A (en) * | 2016-12-10 | 2017-06-16 | 济南昊雨青田医药技术有限公司 | A kind of pharmaceutical composition for treating laryngitis |
-
2015
- 2015-12-03 CN CN201510871918.8A patent/CN105326888A/en not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581100A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for laryngitis treatment and preparation method thereof |
| CN106692261A (en) * | 2016-12-10 | 2017-05-24 | 济南昊雨青田医药技术有限公司 | Pharmaceutical composition for treating laryngitis and preparation method thereof |
| CN106727774A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of pharyngitis and preparation method thereof |
| CN106727859A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof |
| CN106852946A (en) * | 2016-12-10 | 2017-06-16 | 济南昊雨青田医药技术有限公司 | A kind of pharmaceutical composition for treating laryngitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104998098B (en) | It is a kind of to improve the solid beverage slept and preparation method | |
| CN105326888A (en) | Medicinal composition for treating child phlegm-heat obstructing lung type asthma | |
| CN1785024A (en) | Bag-tea for treating pharyngitis and beneficial for throat | |
| CN103719491B (en) | A kind of sealwort invigorating the spleen moistening lung health protection tea and preparation method thereof | |
| CN104547515A (en) | Tangerine pear syrup and preparation method thereof | |
| CN102805776A (en) | Traditional Chinese medicine composition and preparation method of traditional Chinese medicine composition | |
| CN110237174A (en) | A kind of eliminating dampness Chinese medicine composition and preparation method thereof for treating cold cough | |
| CN106511740B (en) | A kind of product and preparation method thereof comprising ginseng | |
| CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
| CN105519731A (en) | Dried tangerine peel tea effervescent tablet and preparation method thereof | |
| CN105250843A (en) | Medicament for treating cough due to wind-heat evil | |
| CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
| CN104383232B (en) | Clearing heat and detoxicating buccal lozenge of lectuce tea and its production method | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
| CN109663012A (en) | Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof | |
| CN108785559A (en) | A kind of drug and preparation method thereof for treating respiratory tract infection | |
| CN104435860B (en) | Traditional Chinese medicinal preparation for treating infantile upper respiratory infection and preparation method of traditional Chinese medicinal preparation | |
| CN1193777C (en) | Chinese medicine for curing cold by omphalotherapy and its preparing process | |
| CN106421591A (en) | Medicinal composition for treating narcolepsy and preparation method of medicinal composition | |
| CN104127504B (en) | Infantile common cold cough syrup and preparation method thereof | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof | |
| CN105288202A (en) | Pharmaceutical composition for curing infantile cough | |
| CN104258361A (en) | Traditional Chinese medicine composition for treating infantile asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160217 |
|
| WW01 | Invention patent application withdrawn after publication |